Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 in Combination With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT06508983Phase 3Recruiting
- Sponsor
- Shangjian Bio
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing SG301 + Pomalidomide + Dexamethasone with Placebo + Pomalidomide + Dexamethasone (2 arms). Primary endpoints: Adverse events, Recommended stage 2 dose of SG301 and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
SG301
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06508983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508983.